> ## Content Index
> Fetch the complete content index at: https://www.coios.me/llms.txt
> Use this file to discover other available public pages before exploring further.

# Brain-derived plasma p-tau217% outperforms standard p-tau217 for Alzheimer's pathology
- URL: https://www.coios.me/brain-derived-plasma-p-tau217-outperforms-standard-p-tau217/
- Published: 2026-11-15T11:36:46.000Z
- Updated: 2026-11-15T12:16:46.000Z
- Description: Brain-derived plasma p-tau217% separated low from severe Alzheimer's neuropathological change with an AUC of 0.93, against 0.90 for standard p-tau217.
- Author: Daniel Ryan
- Tags: Health today, Dementia, #preprint, #refines, #item, #source-2026-11, #score-70

BD-p-tau217% is the proportion of brain-derived plasma tau phosphorylated at threonine 217\. It was tested in autopsy (323), PET (242) and clinical (1,386) cohorts from one Pittsburgh memory clinic. It separated low from severe neuropathological change with an AUC of 0.93, against 0.90 for standard p-tau217\. For amyloid PET it had 92% sensitivity and 88% specificity, against 79% and 82% for p-tau217\. High levels predicted clinical progression, with hazard ratios of 3.21 in clinically unimpaired people and 3.65 in mild cognitive impairment. Limits include a single centre, a 91.5% non-Hispanic White clinical cohort, and no significant AUC gain for unimpaired progressors.

*Why it is interesting: Standard p-tau217 partly comes from tissues outside the brain, which may cloud blood-based diagnosis in older people with other illnesses. Here accuracy stayed at AUC 0.84 to 0.88 among those with comorbidities.*

Source

[medRxiv, 8 November 2026](https://doi.org/10.64898/2026.05.18.26353208?ref=coios.me)

Paper

CNS-selective plasma p-tau217 accurately captures Alzheimer’s disease pathology and progression

Authors

Zeng X, Farinas MF, Nafash MN, Smirnov DS, Shi R, Lopresti BJ et al.

DOI

10.64898/2026.05.18.26353208

Full text

[Open copy](https://pmc.ncbi.nlm.nih.gov/articles/PMC13228684/?ref=coios.me) (open-access copy, PubMed Central)

Type

Preprint

Design

Multi-cohort biomarker validation (neuropathologically defined, amyloid/tau PET-characterised and memory clinic cohorts; follow-up up to 20 years; n not stated)

Verdict

Refines prior evidence

Driver

[Dementia](https://www.coios.me/d-dementia/)